Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10 000 patients and review of the literature

References

• Bowler JV. The concept of vascular cognitive impairment. J Neurol Sci 2002;203­204:11–15
   Google Scholar
• O’Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003;2:89–98
   PubMed Web of Science ®Google Scholar
• Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipo­protein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997;349:151–4
   PubMed Web of Science ®Google Scholar
• Skoog I, Lernfelt B, Landahl S, et al. 15­year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141–5
   PubMed Web of Science ®Google Scholar
• Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20­year follow­up of 999 men. Hypertension 1998;31:780–6
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomised controlled study (MOSES). Stroke 2005;36:1218–26
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359: 995–1003
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double­blind intervention trial. J Hypertens 2003;21:875–86
   PubMed Web of Science ®Google Scholar
• Staessen J, Fagard R, Amery A. Isolated systolic hypertension in the elderly: implications of Systolic Hypertension in the Elderly Program (SHEP) for clinical practice and for the ongoing trials. J Hum Hypertens 1991;5:469–74
   Google Scholar
• Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double­blind placebo­controlled Systolic Hyper tension in Europe (Syst­Eur) trial. Lancet 1998;352:1347–51
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril­based blood­pressure­lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–41
   PubMed Web of Science ®Google Scholar
• Epstein BJ, Gums JG. Can the renin–angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy 2005;25:531–9
   PubMed Web of Science ®Google Scholar
• Richards SS, Emsley CL, Roberts J, et al. The association between vascular risk factor­mediating medications and cognition and dementia diagnosis in a community­based sample of African­Americans. J Am Geriatr Soc 2000;48:1035–41
   PubMed Web of Science ®Google Scholar
• Farmer ME, White LR, Abbott RD, et al. Blood pressure and cognitive performance. The Framingham Study. Am J Epidemiol 1987;126:1103–14
   PubMed Web of Science ®Google Scholar
• Elias MF, Wolf PA, D’Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993;138:353–64
   Google Scholar
• Fratiglioni L, De Ronchi D, Aguero­Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999;15:365–75
   PubMed Web of Science ®Google Scholar
• McGuinness B, Todd S, Passmore P, et al. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2006;:CD004034
   Google Scholar
• Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol 1998;93(Suppl 2):85–91
   Google Scholar
• Toblli JE, Cao G, Casas G, et al. NF­kappaB and chemokinecytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin–angiotensin system. Urol Res 2005;33:358–67
   PubMed Web of Science ®Google Scholar
• Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998;83:1182–91
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33: 613–21
   Google Scholar
• Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000;35(1 Pt 2):155–63
   Google Scholar
• Suzuki G, Mishima T, Tanhehco EJ, et al. Effects of the AT1­receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol 2003;138:301–9
   PubMed Web of Science ®Google Scholar
• Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl 2006;24:S39–43
   PubMedGoogle Scholar
• Brooks DP, Ohlstein EH, Ruffolo RR, Jr. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am Heart J 1999;138(3 Pt 2):246–51
   Google Scholar
• Barone FC, Coatney RW, Chandra S, et al. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke­prone rats. Cardiovasc Res 2001;50:525–37
   PubMed Web of Science ®Google Scholar
• Thone­Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006;24:S115–21
   PubMedGoogle Scholar
• Jonsson L, Lindgren P, Wimo A, et al. Costs of Mini Mental State Examination­related cognitive impairment. Pharmacoeconomics 1999;16:409–16
   PubMed Web of Science ®Google Scholar